$AFIB
Acutus Medical, Inc. Stock $afib

$afib Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000162828023038917 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$7.164M	$5.238M
YoY Change	44.38%	43.74%
Cost Of Revenue	$10.30M	$8.595M
YoY Change	23.8%	23.65%
Gross Profit	-$3.137M	-$3.357M
YoY Change	-6.61%	1.51%
Gross Profit Margin	-43.79%	-64.09%
Selling, General & Admin	$14.07M	$7.432M
YoY Change	48.89%	-23.22%
% of Gross Profit
Research & Development	$3.482M	$4.795M
YoY Change	-44.46%	-19.36%
% of Gross Profit
Depreciation & Amortization	-$3.457M	$1.000M
YoY Change	-337.27%	-33.33%
% of Gross Profit
Operating Expenses	$17.67M	$9.579M
YoY Change	13.16%	-38.69%
Operating Profit	-$20.81M	-$12.94M
YoY Change	9.66%	-36.78%
Interest Expense	-$3.067M	$1.409M
YoY Change	301.97%	27.05%
% of Operating Profit
Other Income/Expense, Net	$2.937M	-$226.0K
YoY Change	-437.2%	-727.78%
Pretax Income	-$11.86M	-$13.16M
YoY Change	-178.06%	-35.56%
Income Tax	$63.00K	$75.00K
% Of Pretax Income
Net Earnings	-$12.13M	-$13.24M
YoY Change	-180.31%	-35.19%
Net Earnings / Revenue	-169.36%	-252.71%
Basic Earnings Per Share		-$0.45
Diluted Earnings Per Share	-$0.41	-$0.45
COMMON SHARES
Basic Shares Outstanding	29.30M shares	29.26M shares
Diluted Shares Outstanding		29.26M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.37M	$38.50M
YoY Change	-68.25%	-41.93%
Cash & Equivalents	$19.17M	$24.10M
Short-Term Investments	$3.200M	$14.40M
Other Short-Term Assets	$8.218M	$9.482M
YoY Change	-36.82%	-3.08%
Inventory	$4.278M	$15.73M
Prepaid Expenses
Receivables	$11.35M	$8.952M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$46.25M	$72.64M
YoY Change	-60.76%	-22.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$825.0K	$6.611M
YoY Change	-93.7%	-34.46%
Goodwill
YoY Change
Intangibles		$1.433M
YoY Change		-12.25%
Long-Term Investments
YoY Change
Other Assets	$94.00K	$688.0K
YoY Change	-89.52%	-30.22%
Total Long-Term Assets	$7.708M	$12.09M
YoY Change	-50.5%	-41.68%
TOTAL ASSETS
Total Short-Term Assets	$46.25M	$72.64M
Total Long-Term Assets	$7.708M	$12.09M
Total Assets	$53.96M	$84.73M
YoY Change	-59.56%	-26.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.761M	$4.754M
YoY Change	-41.52%	2.5%
Accrued Expenses	$2.887M	$7.438M
YoY Change	-71.14%	-16.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.864M	$0.00
YoY Change	3.56%	-100.0%
Total Short-Term Liabilities	$18.94M	$14.77M
YoY Change	-4.68%	-19.4%
LONG-TERM LIABILITIES
Long-Term Debt	$32.65M	$34.76M
YoY Change	-5.17%	1.31%
Other Long-Term Liabilities	$0.00	$32.00K
YoY Change	-100.0%	220.0%
Total Long-Term Liabilities	$32.65M	$34.79M
YoY Change	-15.29%	1.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.94M	$14.77M
Total Long-Term Liabilities	$32.65M	$34.79M
Total Liabilities	$54.84M	$53.02M
YoY Change	-6.13%	-6.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$600.0M	-$566.2M
YoY Change	15.76%	6.15%
Common Stock	$29.00K	$29.00K
YoY Change	0.0%	3.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$879.0K	$31.71M
YoY Change
Total Liabilities & Shareholders Equity	$53.96M	$84.73M
YoY Change	-59.56%	-26.08%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$12.13M	-$13.24M
YoY Change	-180.31%	-35.19%
Depreciation, Depletion And Amortization	-$3.457M	$1.000M
YoY Change	-337.27%	-33.33%
Cash From Operating Activities	-$18.01M	-$14.00M
YoY Change	38.79%	-41.24%
INVESTING ACTIVITIES
Capital Expenditures	-$1.175M	$414.0K
YoY Change	-177.81%	-154.83%
Acquisitions
YoY Change
Other Investing Activities	$10.05M	$17.36M
YoY Change	-26.82%	162.7%
Cash From Investing Activities	$11.22M	$16.95M
YoY Change	-8.16%	189.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-495.0K	-1.939M
YoY Change	3200.0%	323.36%
NET CHANGE
Cash From Operating Activities	-18.01M	-14.00M
Cash From Investing Activities	11.22M	16.95M
Cash From Financing Activities	-495.0K	-1.939M
Net Change In Cash	-7.288M	1.001M
YoY Change	837.97%	-105.43%
FREE CASH FLOW
Cash From Operating Activities	-$18.01M	-$14.00M
Capital Expenditures	-$1.175M	$414.0K
Free Cash Flow	-$16.84M	-$14.42M
YoY Change	16.21%	-37.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24883000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24708000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18272000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15487000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6611000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9221000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	1000000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	1500000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1433000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29303779	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25584000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44863000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5764000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21085000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	13327000	usd
CY2023Q3	afib	Employer Retention Credit Receivable Current Asset EmployerRetentionCreditReceivableCurrentAsset	0	usd
CY2022Q4	afib	Employer Retention Credit Receivable Current Asset EmployerRetentionCreditReceivableCurrentAsset	4703000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2467000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2541000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	117867000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9221000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3872000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1433000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1583000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	897000	usd
CY2022Q4	us-gaap	Assets Assets	133440000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4721000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14767000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3462000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	260000000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	29000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	594173000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-518314000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-869000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	31706000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75019000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	133440000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11401000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23589000	usd
	us-gaap	Gross Profit GrossProfit	-12188000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21884000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38207000	usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	1331000	usd
	us-gaap	Restructuring Charges RestructuringCharges	475000	usd
	us-gaap	Restructuring Charges RestructuringCharges	2280000	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	198000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	123000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	1153000	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	2648000	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	5927000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	43575000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	9579000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	17154000	usd
	us-gaap	Operating Expenses OperatingExpenses	38663000	usd
	us-gaap	Operating Expenses OperatingExpenses	31975000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12936000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20461000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-47414000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44163000	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7947000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-636000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-904000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1478000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-904000	usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	241000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	2223000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-409000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10561000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13162000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13299000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20737000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47982000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.65
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29262768	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28359516	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29024353	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28273207	shares
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43741000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-66000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1264000	usd
CY2022Q4	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax	12000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44863000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	44870000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44863000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001522860
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9686000	usd
CY2023Q3	afib	Short Term Contingent Consideration ShortTermContingentConsideration	0	usd
CY2022Q4	afib	Short Term Contingent Consideration ShortTermContingentConsideration	1800000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	707000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	319000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3346000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34761000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58421000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	6666	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28554656	shares
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	12026000	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	547000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	292000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	1409000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1109000	usd
	us-gaap	Interest Expense InterestExpense	4110000	usd
	us-gaap	Interest Expense InterestExpense	3810000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-226000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20425000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47823000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54724000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-13237000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20425000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-66000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-351000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-91000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29262768	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28359516	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29024353	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28273207	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-13237000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	31706000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	76651000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-351000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1867000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20425000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57781000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75019000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-91000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	4640000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	25000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47898000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	31706000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	105726000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-904000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	66000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	7435000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	182000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54724000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57781000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47898000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54724000	usd
	us-gaap	Depreciation Depreciation	3498000	usd
	us-gaap	Depreciation Depreciation	4653000	usd
	afib	Change In Property Plant And Equipment Converted To Sales ChangeInPropertyPlantAndEquipmentConvertedToSales	-238000	usd
	afib	Change In Property Plant And Equipment Converted To Sales ChangeInPropertyPlantAndEquipmentConvertedToSales	-266000	usd
	us-gaap	Sales Type Lease Selling Profit Loss SalesTypeLeaseSellingProfitLoss	310000	usd
	us-gaap	Sales Type Lease Selling Profit Loss SalesTypeLeaseSellingProfitLoss	87000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	150000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	370000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4915000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7497000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1318000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-237000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	325000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	741000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	513000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	480000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7947000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	12026000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	5927000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	43575000	usd
	afib	Business Disposition Transaction Costs BusinessDispositionTransactionCosts	0	usd
	afib	Business Disposition Transaction Costs BusinessDispositionTransactionCosts	-2917000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1478000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-904000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-268000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	afib	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	123000	usd
	afib	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	1153000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1244000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-420000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2401000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1812000	usd
	afib	Employer Retention Credit Receivable EmployerRetentionCreditReceivable	4703000	usd
	afib	Employer Retention Credit Receivable EmployerRetentionCreditReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-420000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4296000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-495000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-386000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2929000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2430000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-179000	usd
	afib	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-253000	usd
	afib	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-390000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	20000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-40000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45105000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72053000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	17000000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	50000000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	38521000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	33235000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	18599000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	70250000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	59642000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1394000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2473000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	47335000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	92533000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	44550000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1063000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	34825000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	626000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	275000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	62000	usd
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	25000	usd
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	182000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1923000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	873000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2169000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12101000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-294000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-447000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-233000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7932000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31348000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24221000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31115000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32153000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3731000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3101000	usd
	afib	Disposition Of Business Accounts Receivable DispositionOfBusinessAccountsReceivable	6111000	usd
	afib	Disposition Of Business Accounts Receivable DispositionOfBusinessAccountsReceivable	0	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	7000	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	0	usd
	afib	Change In Unpaid Purchases Of Property Plant And Equipment ChangeInUnpaidPurchasesOfPropertyPlantAndEquipment	35000	usd
	afib	Change In Unpaid Purchases Of Property Plant And Equipment ChangeInUnpaidPurchasesOfPropertyPlantAndEquipment	48000	usd
	afib	Financing Costs Incurred But Not Yet Paid FinancingCostsIncurredButNotYetPaid	0	usd
	afib	Financing Costs Incurred But Not Yet Paid FinancingCostsIncurredButNotYetPaid	380000	usd
	afib	Sales Type Lease Net Investment In Lease Noncash SalesTypeLeaseNetInvestmentInLeaseNoncash	238000	usd
	afib	Sales Type Lease Net Investment In Lease Noncash SalesTypeLeaseNetInvestmentInLeaseNoncash	244000	usd
	afib	Proceeds From Issuance Of Long Term Debt Allocated To Warrant Liability ProceedsFromIssuanceOfLongTermDebtAllocatedToWarrantLiability	0	usd
	afib	Proceeds From Issuance Of Long Term Debt Allocated To Warrant Liability ProceedsFromIssuanceOfLongTermDebtAllocatedToWarrantLiability	3379000	usd
CY2023Q3	afib	Cash Cash Equivalents Restricted Cash And Short Term Investments CashCashEquivalentsRestrictedCashAndShortTermInvestments	45500000	usd
CY2022Q4	afib	Cash Cash Equivalents Restricted Cash And Short Term Investments CashCashEquivalentsRestrictedCashAndShortTermInvestments	76200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72100000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566200000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-518300000	usd
CY2023Q3	afib	Working Capital WorkingCapital	57900000	usd
CY2022Q4	afib	Working Capital WorkingCapital	98000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and disclosures of contingent assets and liabilities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2022Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25584000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	7015000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5764000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31115000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31348000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentrations of Credit Risk and Off-Balance Sheet RiskFinancial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, restricted cash, accounts receivable and marketable securities. The Company has not experienced losses on these accounts, and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.
CY2023Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2416000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5238000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3644000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	14696000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11401000	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	300000	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	200000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	900000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	2600000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2025000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2648000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2123000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	15728000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	13327000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8952000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21085000	usd
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	12000000	usd
CY2023Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	35394000	usd
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1868000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	67563000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	5146000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	417000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1583000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	14375000	usd
CY2023Q3	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax	0	usd
CY2023Q3	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax	0	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	14375000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	14375000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	14375000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	44870000	usd
CY2022Q4	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax	5000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	14400000	usd
CY2023Q3	afib	Debt Securities Available For Sale Current Term DebtSecuritiesAvailableForSaleCurrentTerm	P1Y
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44900000	usd
CY2022Q4	afib	Debt Securities Available For Sale Current Term DebtSecuritiesAvailableForSaleCurrentTerm	P1Y
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10664000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9179000	usd
CY2023Q3	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	0	usd
CY2022Q3	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	0	usd
	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	500000	usd
	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	300000	usd
	us-gaap	Depreciation Depreciation	3500000	usd
	us-gaap	Depreciation Depreciation	4700000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1583000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	150000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2000000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	567000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1433000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2000000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	50000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	200000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	200000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	200000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	200000	usd
CY2023Q3	afib	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	583000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1433000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5264000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6919000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	192000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	126000	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	349000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	326000	usd
CY2023Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	187000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	639000	usd
CY2023Q3	afib	Clinical Studies Current ClinicalStudiesCurrent	374000	usd
CY2022Q4	afib	Clinical Studies Current ClinicalStudiesCurrent	390000	usd
CY2023Q3	afib	Clinical Accounts Current ClinicalAccountsCurrent	241000	usd
CY2022Q4	afib	Clinical Accounts Current ClinicalAccountsCurrent	216000	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	108000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	159000	usd
CY2023Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	35000	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	45000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	688000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	866000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7438000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9686000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1160000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	36750000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	36776000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	1989000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	2342000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34761000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34434000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	282000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	631000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	252000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	252000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	755000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	768000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	81000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	77000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	243000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	216000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	333000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	329000	usd
	us-gaap	Lease Cost LeaseCost	998000	usd
	us-gaap	Lease Cost LeaseCost	984000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	138000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1151000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1185000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1221000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4855000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	686000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4169000	usd
CY2022Q1	afib	Number Of Class Action Lawsuits NumberOfClassActionLawsuits	2	lawsuit
CY2022Q3	afib	Number Of Class Action Lawsuits Consolidated NumberOfClassActionLawsuitsConsolidated	2	lawsuit
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4576505	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4576505	shares
	afib	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1500000	usd
	afib	Number Of Warrant Holders NumberOfWarrantHolders	4	holder
	afib	Conversion Of Stock Maximum Number Of Shares Held After Conversion Percentage Of Common Stock Outstanding ConversionOfStockMaximumNumberOfSharesHeldAfterConversionPercentageOfCommonStockOutstanding	0.049
CY2023Q3	afib	Number Of Warrant Holders With Ability To Increase Stock Ownership Percentage After Written Notice Election NumberOfWarrantHoldersWithAbilityToIncreaseStockOwnershipPercentageAfterWrittenNoticeElection	2	holder
	afib	Conversion Of Stock Maximum Number Of Shares Held After Conversion Percentage Of Common Stock Outstanding After Written Notice Election ConversionOfStockMaximumNumberOfSharesHeldAfterConversionPercentageOfCommonStockOutstandingAfterWrittenNoticeElection	0.099
CY2021Q3	afib	Number Of Investors NumberOfInvestors	4	investor
CY2021Q3	afib	Conversion Of Stock Maximum Number Of Shares Held After Conversion Percentage Of Common Stock Outstanding ConversionOfStockMaximumNumberOfSharesHeldAfterConversionPercentageOfCommonStockOutstanding	0.049
CY2021Q3	afib	Common Stock Conversion Written Notice Election Period CommonStockConversionWrittenNoticeElectionPeriod	P61D
CY2021Q3	afib	Conversion Of Stock Maximum Number Of Shares Held After Conversion Percentage Of Common Stock Outstanding After Written Notice Election ConversionOfStockMaximumNumberOfSharesHeldAfterConversionPercentageOfCommonStockOutstandingAfterWrittenNoticeElection	0.099
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0391
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0427
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0176
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0339
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.90
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2898821	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	79000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	755580	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.28
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3218	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.34
	afib	Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueExercised	1000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1562043	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.72
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2089140	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.93
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1098279	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.43
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	23000	usd
	afib	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Grant Date Fair Value Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageGrantDateFairValueExercisePrice	0.70
CY2022	afib	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Grant Date Fair Value Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageGrantDateFairValueExercisePrice	1.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.87
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2300000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1278000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1884000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4915000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7497000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14692714	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16271309	shares
CY2022Q2	afib	Piggy Back Registration Rights Period PiggyBackRegistrationRightsPeriod	P5Y
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001

Files In Submission

Name	View Source	Status
afib-20230930_pre.xml	Edgar Link	unprocessable
afib-20230930_cal.xml	Edgar Link	unprocessable
0001628280-23-038917-index-headers.html	Edgar Link	pending
0001628280-23-038917-index.html	Edgar Link	pending
0001628280-23-038917.txt	Edgar Link	pending
0001628280-23-038917-xbrl.zip	Edgar Link	pending
afib-20230930.htm	Edgar Link	pending
afib-20230930.xsd	Edgar Link	pending
afib-20230930x10qex311.htm	Edgar Link	pending
afib-20230930x10qex312.htm	Edgar Link	pending
afib-20230930x10qex321.htm	Edgar Link	pending
afib-20230930x10qex322.htm	Edgar Link	pending
afib-20230930_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
afib-20230930_lab.xml	Edgar Link	unprocessable
afib-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
afib-20230930_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AFIB
Acutus Medical, Inc. Stock $afib

2023 Q4 Form 10-Q Financial Statement

#000162828023038917 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AFIB Acutus Medical, Inc. Stock $afib

2023 Q4 Form 10-Q Financial Statement

#000162828023038917 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AFIB
Acutus Medical, Inc. Stock $afib